Exelixis Inc (EXEL) 5.65 $EXEL
Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 5:46AM CDT
Can the Rally in Exelixis (EXEL) Shares Continue?
EXEL: 5.65 (+0.24)
Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015
Business Wire - Tue Jul 28, 3:34PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.
EXEL: 5.65 (+0.24)
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:00PM CDT
Exelixis (EXEL) has a Zacks Rank #2 with an earnings ESP of -9.52% and is expected to report second-quarter 2015 results on Jul 30.
MNK: 124.00 (+0.13), PRGO: 193.00 (+0.93), TEVA: 71.01 (-0.40), EXEL: 5.65 (+0.24)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 156.97 (-3.35), BIIB: 310.39 (-9.54), LGND: 103.27 (-2.57), REGN: 541.25 (-11.20), EXEL: 5.65 (+0.24)
Exelixis (EXEL) Stock Falls on Upsized Secondary Offering
at The Street - Mon Jul 27, 2:43PM CDT
Exelexis (EXEL) shares are down after the company added 5 million shares to its secondary offering.
EXEL: 5.65 (+0.24)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 156.97 (-3.35), BIIB: 310.39 (-9.54), LGND: 103.27 (-2.57), AMGN: 170.78 (-1.96), REGN: 541.25 (-11.20), EXEL: 5.65 (+0.24), CELG: 133.16 (-2.26)
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 2.06 (-0.49), AZN: 32.83 (+0.02), AMGN: 170.78 (-1.96), EXEL: 5.65 (+0.24)
3 Biotech Stocks That Could Double Before 2016
George Budwell, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 26, 7:54AM CDT
Small-cap biotech stocks have the ability to produce eye-popping gains -- and even double, in short order. In the same breath, they also have the capacity to wreak havoc on your portfolio if things go the wrong way in the clinic or on the regulatory...
ONCE: 59.53 (-0.79), GERN: 4.11 (-0.11), EXEL: 5.65 (+0.24)
How to Trade 4 of the Market's Most Active Stocks
at The Street - Fri Jul 24, 1:45PM CDT
Here's a technical look at how to trade some of the most actives stocks on the market right now.
AMZN: 527.21 (+1.18), P: 16.84 (+0.01), GDX: 13.77 (+0.08), EXEL: 5.65 (+0.24)
Positive Results From Phase 3 Clinical Trial of Cabozantinib - Report on Exelixis
PR Newswire - Fri Jul 24, 8:05AM CDT
ACI Association has initiated research coverage on Exelixis, Inc. (NASDAQ: EXEL). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
EXEL: 5.65 (+0.24)
Exelixis prices public offering of common stock at USD5.40 per share
M2 - Fri Jul 24, 5:22AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Thursday that it has priced its public offering of 25,000,000 shares of its newly issued common stock.
EXEL: 5.65 (+0.24)
Exelixis Prices Public Offering of Common Stock
Business Wire - Thu Jul 23, 7:08PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced the pricing of its underwritten public offering of 25,000,000 shares of newly issued common stock at a price to the public of $5.40 per share. The gross proceeds to Exelixis from this offering are expected to be approximately $135 million, before deducting the underwriting discount and other estimated offering expenses payable by Exelixis. Exelixis also granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its common stock. All of the shares are being sold by Exelixis.
EXEL: 5.65 (+0.24)
Critical Alerts For Lumber Liquidators, Exelixis, Ford, Intuitive Surgical and Rite Aid Released By InvestorsObserver
PR Newswire - Thu Jul 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LL, EXEL, F, ISRG and RAD.
ISRG: 539.72 (-0.54), F: 15.09 (+0.26), LL: 18.78 (-0.18), RAD: 8.89 (+0.14), EXEL: 5.65 (+0.24)
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie
AMGN: 170.78 (-1.96), ABBV: 71.27 (+0.04), REGN: 541.25 (-11.20), FPRX: 22.84 (-1.24), EXEL: 5.65 (+0.24)
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4277fl/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs - Bevacizumab (Avastin) - Temozolomide (Temodar and Temodal and Temcad) - Carmustine (BiCNU) Global Pipeline Review of Glioblastoma Treatment - Overview - Late Stage (Phase III) - - DCVax - - Rindopepimut (CDX-110) - - Others - Early Stage (Phase I, II and Pre clinical) - - ABT-414 - - MM-398 - - ARC-100 - - AV0113 - - Cotara - - Crenolanib - - SGT-53 - - Endostatin - - ANG1005 - Others Companies Mentioned - AbbVie, Inc. - Activartis GmbH - Agenus Inc. - Arog Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) - Cavion LLC - Celldex Therapeutics Inc. - Cortice Biosciences Inc. - Eisai Co., Ltd. - Exelixis Inc. - F. Hoffmann-La Roche Ltd. - Merrimack Pharmaceuticals, Inc. - OncoSynergy - Peregrine Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ioblastoma
MACK: 10.16 (-0.14), CLDX: 23.70 (-0.82), ABBV: 71.27 (+0.04), CTIC: 1.88 (-0.05), BMY: 64.39 (-0.27), EXEL: 5.65 (+0.24)
Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 22, 9:52AM CDT
Amgen's (AMGN) potential blockbuster, Repatha, is the first PCSK9 inhibitor to gain approval in the world for the treatment of high cholesterol.
BIIB: 310.50 (-9.43), ALXN: 202.40 (-1.15), AMGN: 170.78 (-1.96), ABBV: 71.27 (+0.04), REGN: 541.25 (-11.20), FPRX: 22.84 (-1.24), EXEL: 5.65 (+0.24)
Exelixis (EXEL) Stock Declines on Secondary Public Offering
at The Street - Wed Jul 22, 8:54AM CDT
Exelixis (EXEL) shares are falling after the company announced the public offering of 20 million shares, just days after the stock spiked 50% on positive trial data.
EXEL: 5.65 (+0.24)
Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis, XOMA Corp., Theravance, and NewLink Genetics
PR Newswire - Wed Jul 22, 8:22AM CDT
Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Theravance Inc. (NASDAQ: THRX), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research report on Amgen can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AMGN On Tuesday, July 21, 2015, the NASDAQ Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial Average declined 1.00%, to finish the day at 17,919.29, and the S&P 500 closed at 2,119.21, down 0.43%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
NLNK: 51.19 (-2.62), AMGN: 170.78 (-1.96), THRX: 15.65 (-0.34), XOMA: 0.83 (-0.05), EXEL: 5.65 (+0.24)
Exelixis proposes public offering of 20m common stock
M2 - Wed Jul 22, 4:33AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Tuesday that it intends to issue 20,000,000 shares of its common stock in an underwritten public offering.
EXEL: 5.65 (+0.24)
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:40PM CDT
Exelixis' (EXEL) Cometriq scores in a late-stage study (METEOR) in patients with metastatic renal cell carcinoma.
EBIO: 2.80 (+0.04), AMAG: 64.42 (-1.81), NVS: 103.77 (+0.98), EXEL: 5.65 (+0.24)
Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 5:46AM CDT
Can the Rally in Exelixis (EXEL) Shares Continue?
EXEL: 5.65 (+0.24)
Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015
Business Wire - Tue Jul 28, 3:34PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.
EXEL: 5.65 (+0.24)
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:00PM CDT
Exelixis (EXEL) has a Zacks Rank #2 with an earnings ESP of -9.52% and is expected to report second-quarter 2015 results on Jul 30.
MNK: 124.00 (+0.13), PRGO: 193.00 (+0.93), TEVA: 71.01 (-0.40), EXEL: 5.65 (+0.24)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 156.97 (-3.35), BIIB: 310.39 (-9.54), LGND: 103.27 (-2.57), REGN: 541.25 (-11.20), EXEL: 5.65 (+0.24)
Exelixis (EXEL) Stock Falls on Upsized Secondary Offering
at The Street - Mon Jul 27, 2:43PM CDT
Exelexis (EXEL) shares are down after the company added 5 million shares to its secondary offering.
EXEL: 5.65 (+0.24)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 156.97 (-3.35), BIIB: 310.39 (-9.54), LGND: 103.27 (-2.57), AMGN: 170.78 (-1.96), REGN: 541.25 (-11.20), EXEL: 5.65 (+0.24), CELG: 133.16 (-2.26)
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 2.06 (-0.49), AZN: 32.83 (+0.02), AMGN: 170.78 (-1.96), EXEL: 5.65 (+0.24)
3 Biotech Stocks That Could Double Before 2016
George Budwell, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 26, 7:54AM CDT
Small-cap biotech stocks have the ability to produce eye-popping gains -- and even double, in short order. In the same breath, they also have the capacity to wreak havoc on your portfolio if things go the wrong way in the clinic or on the regulatory...
ONCE: 59.53 (-0.79), GERN: 4.11 (-0.11), EXEL: 5.65 (+0.24)
How to Trade 4 of the Market's Most Active Stocks
at The Street - Fri Jul 24, 1:45PM CDT
Here's a technical look at how to trade some of the most actives stocks on the market right now.
AMZN: 527.21 (+1.18), P: 16.84 (+0.01), GDX: 13.77 (+0.08), EXEL: 5.65 (+0.24)
Positive Results From Phase 3 Clinical Trial of Cabozantinib - Report on Exelixis
PR Newswire - Fri Jul 24, 8:05AM CDT
ACI Association has initiated research coverage on Exelixis, Inc. (NASDAQ: EXEL). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
EXEL: 5.65 (+0.24)
Exelixis prices public offering of common stock at USD5.40 per share
M2 - Fri Jul 24, 5:22AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Thursday that it has priced its public offering of 25,000,000 shares of its newly issued common stock.
EXEL: 5.65 (+0.24)
Exelixis Prices Public Offering of Common Stock
Business Wire - Thu Jul 23, 7:08PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today announced the pricing of its underwritten public offering of 25,000,000 shares of newly issued common stock at a price to the public of $5.40 per share. The gross proceeds to Exelixis from this offering are expected to be approximately $135 million, before deducting the underwriting discount and other estimated offering expenses payable by Exelixis. Exelixis also granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its common stock. All of the shares are being sold by Exelixis.
EXEL: 5.65 (+0.24)
Critical Alerts For Lumber Liquidators, Exelixis, Ford, Intuitive Surgical and Rite Aid Released By InvestorsObserver
PR Newswire - Thu Jul 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LL, EXEL, F, ISRG and RAD.
ISRG: 539.72 (-0.54), F: 15.09 (+0.26), LL: 18.78 (-0.18), RAD: 8.89 (+0.14), EXEL: 5.65 (+0.24)
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie
AMGN: 170.78 (-1.96), ABBV: 71.27 (+0.04), REGN: 541.25 (-11.20), FPRX: 22.84 (-1.24), EXEL: 5.65 (+0.24)
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4277fl/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs - Bevacizumab (Avastin) - Temozolomide (Temodar and Temodal and Temcad) - Carmustine (BiCNU) Global Pipeline Review of Glioblastoma Treatment - Overview - Late Stage (Phase III) - - DCVax - - Rindopepimut (CDX-110) - - Others - Early Stage (Phase I, II and Pre clinical) - - ABT-414 - - MM-398 - - ARC-100 - - AV0113 - - Cotara - - Crenolanib - - SGT-53 - - Endostatin - - ANG1005 - Others Companies Mentioned - AbbVie, Inc. - Activartis GmbH - Agenus Inc. - Arog Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) - Cavion LLC - Celldex Therapeutics Inc. - Cortice Biosciences Inc. - Eisai Co., Ltd. - Exelixis Inc. - F. Hoffmann-La Roche Ltd. - Merrimack Pharmaceuticals, Inc. - OncoSynergy - Peregrine Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ioblastoma
MACK: 10.16 (-0.14), CLDX: 23.70 (-0.82), ABBV: 71.27 (+0.04), CTIC: 1.88 (-0.05), BMY: 64.39 (-0.27), EXEL: 5.65 (+0.24)
Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 22, 9:52AM CDT
Amgen's (AMGN) potential blockbuster, Repatha, is the first PCSK9 inhibitor to gain approval in the world for the treatment of high cholesterol.
BIIB: 310.50 (-9.43), ALXN: 202.40 (-1.15), AMGN: 170.78 (-1.96), ABBV: 71.27 (+0.04), REGN: 541.25 (-11.20), FPRX: 22.84 (-1.24), EXEL: 5.65 (+0.24)
Exelixis (EXEL) Stock Declines on Secondary Public Offering
at The Street - Wed Jul 22, 8:54AM CDT
Exelixis (EXEL) shares are falling after the company announced the public offering of 20 million shares, just days after the stock spiked 50% on positive trial data.
EXEL: 5.65 (+0.24)
Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis, XOMA Corp., Theravance, and NewLink Genetics
PR Newswire - Wed Jul 22, 8:22AM CDT
Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Theravance Inc. (NASDAQ: THRX), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research report on Amgen can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AMGN On Tuesday, July 21, 2015, the NASDAQ Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial Average declined 1.00%, to finish the day at 17,919.29, and the S&P 500 closed at 2,119.21, down 0.43%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
NLNK: 51.19 (-2.62), AMGN: 170.78 (-1.96), THRX: 15.65 (-0.34), XOMA: 0.83 (-0.05), EXEL: 5.65 (+0.24)
Exelixis proposes public offering of 20m common stock
M2 - Wed Jul 22, 4:33AM CDT
Biopharmaceutical company Exelixis (Nasdaq:EXEL) said on Tuesday that it intends to issue 20,000,000 shares of its common stock in an underwritten public offering.
EXEL: 5.65 (+0.24)
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:40PM CDT
Exelixis' (EXEL) Cometriq scores in a late-stage study (METEOR) in patients with metastatic renal cell carcinoma.
EBIO: 2.80 (+0.04), AMAG: 64.42 (-1.81), NVS: 103.77 (+0.98), EXEL: 5.65 (+0.24)
